Press

2024-11-01

Kancera appoints Robert Edfors as Chief Medical Officer

Kancera AB (publ) today announces that Robert Edfors is appointed as Chief Medical Officer (CMO) at Kancera, effective on November 1, 2024. Robert Edfors, specialist in cardiology and internal medicine, has up until now been the company’s Chief Scientific...

Read More
2024-08-23

Kancera gives an operational update concerning its clinical development program

In connection with the interim report for the second quarter 2024, Kancera AB (publ) today provides a general operational update concerning its clinical development program and reports that: the phase IIa part in the KANDOVA study has been initiated...

Read More
2024-08-23

Interim Report Second Quarter 2024, April 1 – June 30, Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the second quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 9,7 million (SEK 16,5 million). Operating loss for the quarter amounted to...

Read More
2024-07-18

Kancera’s FRACTAL study results to be presented at the ESC 2024 Conference

Kancera AB (publ) announces that the results from the FRACTAL study will be presented at the European Society of Cardiology (ESC) annual conference on September 2, 2024.

Read More
2024-07-11

Phase Ib completed and the recommended phase II dose is set in the ongoing KANDOVA study

Kancera AB (publ) today reports that the first part, phase Ib, has been successfully completed in the ongoing KANDOVA study, a combined phase Ib/IIa study of Kancera’s candidate drug KAND567 in ovarian cancer in combination with carboplatin. The objective...

Read More
2024-05-17

Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the first quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million) R&D expenses amounted to SEK 11,4 million (SEK 15,2 million) Operating loss for the quarter amounted to...

Read More
2024-05-16

Kancera provides operational update regarding the KANDOVA study and reports increased patient recruitment

In connection with the upcoming Interim Report for the first quarter 2024, Kancera AB (publ) provides an operational update regarding KANDOVA, a combined phase Ib/IIa study of KAND567 in ovarian cancer, and reports that: The patient recruitment pace has...

Read More
2024-05-08

Kancera appoints new Chief Scientific Officer and extends management team

Kancera AB (publ) today announces that Robert Edfors is appointed as new Chief Scientific Officer and Senior Vice President Clinical Development and that the management team is extended with two new positions.

Read More
2024-05-03

Kancera meets the primary objectives of the KAND145 clinical phase I study

Kancera AB (publ) today reports positive results from the clinical phase I study with KAND145 in healthy subjects and that the primary objectives of the study were met: KAND145 is safe and tolerable at maximum exposure when administered as...

Read More
2024-03-20

Kancera announces the outcome of the company’s rights issue

The board of directors of Kancera AB (”Kancera” or the ”Company”), hereby announces the outcome of the Company's rights issue of shares with preferential rights for the Company's existing shareholders and which was covered by subscription and guarantee commitments...

Read More